The present study demonstrated that inhibiting ENTPD1 can enhance the anticancer efficacy of ceritinib in triple negative breast cancer, melanoma cells, and non‐small cell lung cancer [21]. The gene discussed is ENTPD1; the disease is triple-negative breast carcinoma.